Global Porcine Vaccine Market Size (2024 - 2029)

Porcine Vaccines Market Analysis

The Global Porcine Vaccine Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.95 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).

The sudden outbreak of COVID-19 majorly impacted all the markets. With the focus primarily shifted to combat COVID-19, all other research and development are on hold. In July 2020, the Center for Disease Control and Prevention (CDC) provided specific guidelines to veterinary professionals for treating animals during COVID-19. Many government agencies have also recommended prioritizing urgent and emergency visits to clinics and hospitals. Furthermore, most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the global shortage of healthcare facilities and COVID-19 testing laboratories, according to the OIE (World Organization for Animal Health). However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. Prestige Animal Hospitals, for example, has taken precautionary measures when treating animals. It also launched the 'Drop Off Exams' program, which allows owners to drop off their pets for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. As a result, the companion animal vaccine market is experiencing a slight short-term negative impact, owing to lower veterinary visits during COVID-19. Thus, COVID-19 is expected to impact the porcine vaccine market slightly.

Additionally, the growing R&D activities by the key players for discovering novel porcine vaccines to treat diseases and rising product approvals are expected to aid in the positive growth of the studied market over the forecast period. For instance, in May 2021, the Classical Swine Fever (CSF) vaccine was launched under the Raksha Class by Indian Immunologicals Limited (IIL) brand name. Thus, rising product launches anticipated market growth over the forecast period.

According to the Congress Budget Office report in April 2021, the pharmaceutical industry spent USD 83 billion on research and development. These costs were paid for various activities, including discovering and testing new drugs, developing incremental innovations like product extensions, and conducting clinical trials for safety monitoring or marketing purposes. Thus rising in R&D spending boosts the market over the forecast period.

PRRS (Porcine Reproductive and Respiratory Syndrome) is still a common disease in pig farms, causing financial losses due to its adverse effects on reproduction, growth, and clinical illness. As a result, market innovation to meet customer demand has been ongoing. For example, in April 2021, Ahmedabad-based company Hester Bioscience got the right to commercially produce classical swine fever and sheep pox vaccines in India. Scientists develop these two vaccines from the Indian Veterinary Research Institute (IVRI), Izatnagar, under the Indian Council of Agricultural Research (ICAR). Also, in April 2021, the Argentine laboratory Vetanco partnered with Pharmgate Animal Health to distribute the Circo/MycoGard vaccine in Argentina and Latin America. The vaccine protects pigs against both PCV-2 and Mycoplasma hyopneumoniae.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, high expenses of maintaining and handling storage conditions and chance of reverse reaction from vaccines significantly hinder the market's growth.

Porcine Vaccines Industry Segmentation

Porcine Vaccines are a clinical and administrative drug that ameliorates swine health by protecting them from various bacteria, viruses, and other pathogens. The market is segmented by Target Disease (Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD), Other Target Diseases), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.